Business Description
Zimmer Biomet Holdings Inc
NAICS : 339113
SIC : 3842
ISIN : US98956P1021
Total Employee Number:
17,000Compare
Compare
Traded in other countries / regions
ZBH.USAZBH.AustriaZ1BH34.BrazilZIM.Germany1ZBH.ItalyZBH.Switzerland0QQD.UKZBH.Mexico Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
2001-08-07Description
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.59 | |||||
Debt-to-EBITDA | 3.21 | |||||
Interest Coverage | 4.81 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.53 | |||||
Beneish M-Score | -2.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.9 | |||||
3-Year EBITDA Growth Rate | 16.2 | |||||
3-Year EPS without NRI Growth Rate | 6 | |||||
3-Year FCF Growth Rate | 12.1 | |||||
3-Year Book Growth Rate | 4.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.81 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.95 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.39 | |||||
9-Day RSI | 58.53 | |||||
14-Day RSI | 58.97 | |||||
3-1 Month Momentum % | 15.61 | |||||
6-1 Month Momentum % | -2.73 | |||||
12-1 Month Momentum % | -8.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.69 | |||||
Quick Ratio | 0.94 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 334.37 | |||||
Days Sales Outstanding | 72.17 | |||||
Days Payable | 47.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.95 | |||||
Dividend Payout Ratio | 0.11 | |||||
Forward Dividend Yield % | 0.95 | |||||
5-Year Yield-on-Cost % | 0.96 | |||||
3-Year Average Share Buyback Ratio | 2.2 | |||||
Shareholder Yield % | 0.72 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.87 | |||||
Operating Margin % | 16.34 | |||||
Net Margin % | 9.48 | |||||
EBITDA Margin % | 27.4 | |||||
FCF Margin % | 16.47 | |||||
OCF Margin % | 20.49 | |||||
ROE % | 6.37 | |||||
ROA % | 3.51 | |||||
ROIC % | 5.56 | |||||
3-Year ROIIC % | 19.3 | |||||
ROC (Joel Greenblatt) % | 24.81 | |||||
ROCE % | 6.03 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.49 | |||||
Forward PE Ratio | 11.83 | |||||
PE Ratio without NRI | 11.9 | |||||
Shiller PE Ratio | 27.23 | |||||
Price-to-Owner-Earnings | 13 | |||||
PEG Ratio | 0.69 | |||||
PS Ratio | 2.33 | |||||
PB Ratio | 1.52 | |||||
Price-to-Free-Cash-Flow | 14.14 | |||||
Price-to-Operating-Cash-Flow | 11.36 | |||||
EV-to-EBIT | 21.53 | |||||
EV-to-Forward-EBIT | 19.58 | |||||
EV-to-EBITDA | 11.29 | |||||
EV-to-Forward-EBITDA | 12.13 | |||||
EV-to-Revenue | 3.09 | |||||
EV-to-Forward-Revenue | 3.06 | |||||
EV-to-FCF | 18.78 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Projected-FCF | 0.75 | |||||
Price-to-Median-PS-Value | 0.73 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.2 | |||||
Earnings Yield (Greenblatt) % | 4.64 | |||||
FCF Yield % | 7.28 | |||||
Forward Rate of Return (Yacktman) % | 15.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:ZBH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zimmer Biomet Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8,508.8 | ||
| EPS (TTM) ($) | 4.12 | ||
| Beta | 0.1856 | ||
| 3-Year Sharpe Ratio | -0.57 | ||
| 3-Year Sortino Ratio | -0.75 | ||
| Volatility % | 29.36 | ||
| 14-Day RSI | 58.97 | ||
| 14-Day ATR ($) | 2.664624 | ||
| 20-Day SMA ($) | 98.942 | ||
| 12-1 Month Momentum % | -8.86 | ||
| 52-Week Range ($) | 79.12 - 106.88 | ||
| Shares Outstanding (Mil) | 190.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zimmer Biomet Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zimmer Biomet Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-19 | In 174 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-10 08:30 | In 166 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-10 06:30 | In 166 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 08:30 | In 69 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 06:30 | In 69 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:30 | 95.81 (+0.34%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 06:30 | 95.81 (+0.34%) | ||
| USD 0.240000 Cash Dividend | 2026-06-25 | 90.56 (+2.89%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 10:40 | 87.33 (-0.31%) | ||
| General meeting for 2026 | 2026-05-22 09:30 | 85.31 (+0.80%) |
Show
Entries
Zimmer Biomet Holdings Inc Frequently Asked Questions
What is Zimmer Biomet Holdings Inc(ZBH)'s stock price today?
The current price of ZBH is $100.91. The 52 week high of ZBH is $106.88 and 52 week low is $79.12.
When is next earnings date of Zimmer Biomet Holdings Inc(ZBH)?
The next earnings date of Zimmer Biomet Holdings Inc(ZBH) is 2026-11-05 Est..
Does Zimmer Biomet Holdings Inc(ZBH) pay dividends? If so, how much?
The Dividend Yield %  of Zimmer Biomet Holdings Inc(ZBH) is 0.95% (As of Today), Highest Dividend Payout Ratio of Zimmer Biomet Holdings Inc(ZBH) was 0.17. The lowest was 0.11. And the median was 0.12. The  Forward Dividend Yield % of Zimmer Biomet Holdings Inc(ZBH) is 0.95%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:ZBH
Long Cast Advisers
Bullish
2026 Q2
What the manager wrote
Zimmer's purchase of Monogram last year included 'contingent valuation rights' (CVRs) that pay out $3.41 / share in each year from 2028 to 2030 that mBos gross revenues exceed certain hurdles. Based on these estimates, we calculated the number of systems needed to achieve those revenues, and it triangulates to a capital sale in the range of ~$1M per machine, in line with the cost of Stryker’s Mako platform. Stryker sold 860 units in its first three years, so the forecast 609 units to trigger the final CVR seems achievable. And even if the timing is wrong or our estimates imprecise, as long as the direction is right - and Zimmer is putting significant resources behind the launch - once the system launches, PDEX could experience an exceptional transformation in operating cash flow that would justify a substantially higher corporate value. This is why it remains a top position.
Matrix Large Cap Value Strategy
Bearish
2026 Q1
What the manager wrote
Zimmer Biomet was a disappointing holding. The company should be a good business, but management exhausted our patience after years of missteps. We sold the full position in Zimmer Biomet as we no longer have confidence in its management and performance.
Press Release
Articles on Zimmer Biomet Holdings Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers